MedTrace Logo

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

NCT00293800 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 173

Last updated 2012-02-14

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and effectiveness of an investigational glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution

Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

DRUG

Latanoprost 0.005% Ophthalmic Solution (XALATAN)

Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

DRUG

Timolol 0.5% Ophthalmic Solution

Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension

OTHER

Timolol Vehicle

Placebo

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2005-12-31
Completion
2005-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293800 on ClinicalTrials.gov